A Phase 1b study to investigate safety and tolerability of ARGX-119 in adult participants with DOK7 Congenital Myasthenic Syndrome (CMS)
ARGX-119-2302
Phase 2 other active
Quick answer
A Phase 1b study to investigate safety and tolerability of ARGX-119 in adult participants with DOK7 Congenital Myasthenic Syndrome (CMS) for congenital neuromuscular disorders is a Phase 2 program (other) at Argenx with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Argenx
- Indication
- congenital neuromuscular disorders
- Phase
- Phase 2
- Modality
- other
- Status
- active